Mode
Text Size
Log in / Sign up

Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary diseaseDoctors found that bladder cancer returning later has higher risk of coming back again

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that metachronous NMIBC after UTUC may have worse BCG outcomes than primary NMIBC, informing risk stratification.

This is a systematic review and meta-analysis of studies comparing outcomes in patients with primary non-muscle invasive bladder cancer (p-NMIBC) versus metachronous non-muscle invasive bladder cancer (m-NMIBC) following prior upper tract urothelial carcinoma treatment, all receiving BCG. The meta-analysis included 1292 patients.

For high-grade recurrence-free survival, m-NMIBC was associated with worse outcomes than p-NMIBC (hazard ratio 0.47 in one-stage analysis; HR 0.44 in two-stage analysis; 95% CI 0.38-0.59 and 0.38-0.50, respectively; P < 0.001 for both). Progression-free survival was also worse for m-NMIBC (HR 0.54 one-stage; HR 0.45 two-stage; 95% CI 0.35-0.83 and 0.22-0.90; P = 0.005 and P = 0.035). Cancer-specific survival and overall survival showed no significant differences (CSS HR 0.53, 95% CI 0.24-1.17, P = 0.116; OS HR 1.24, 95% CI 0.64-2.42, P = 0.520).

The authors acknowledged a moderate overall risk of bias across the included studies. Safety data were not reported. The review highlights implications for clinical trial design and risk stratification, but the evidence is observational and does not establish causation.

This study looked at many patients who had bladder cancer that did not spread deeply into muscle. Some of these patients had cancer in their upper urinary tract before. Now, they are getting a special treatment called BCG to stop the cancer from returning.

The main finding is that patients whose bladder cancer comes back later have a harder time staying free of high-grade cancer. Their risk of the cancer returning is much higher than for people with their first bladder cancer diagnosis.

The study also checked if the cancer would get worse or if patients would die from it. Results showed a lower chance of the cancer getting worse for the later group. However, there was no big difference in how long people lived or died from cancer alone.

Doctors say this helps them plan better tests and treatments. It is important to watch patients carefully if their cancer returns after a previous kidney cancer treatment. This helps doctors decide who needs extra care sooner.

What this means for you:
Patients with bladder cancer returning after prior kidney cancer treatment face higher risks of recurrence and progression.

Study Details

Study typeMeta analysis
Sample sizen = 1,292
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
INTRODUCTION: Emerging evidence suggests that metachronous non-muscle invasive bladder cancer (m-NMIBC) recurrence after prior upper tract urothelial carcinoma (UTUC) treatment is distinct from primary NMIBC (p-NMIBC). Correspondingly, their disease trajectories and treatment responses may differ vastly. This systematic review aims to evaluate the differences in Bacillus Calmette-Guérin (BCG) response between m-NMIBC and p-NMIBC. METHODS: A comprehensive literature search (PubMed, Embase, and Scopus) was performed to identify relevant studies that reported BCG outcomes for p-NMIBC and m-NIMBC. Endpoints analyzed were high-grade recurrence-free survival (HG-RFS), progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS). This study followed the PRISMA guidelines. Both one-stage and two-stage meta-analyses were performed. RESULTS: Six cohort studies with 1,292 patients were identified. Three studies utilized propensity-matched scoring to account for differences in baseline clinical characteristics. BCG prescription was observed in 89% of the whole cohort, with 4 studies treating all included patients with BCG. Patients with m-NMIBC demonstrated worse HG-RFS (one-stage meta-analysis: HR 0.47, 95% CI 0.38-0.59, P < 0.001; two-stage meta-analysis: HR 0.44, 95% CI 0.38-0.50, P < 0.001, I² = 0%). M-NMNIBC also demonstrated worse PFS compared to p-NMIBC (one-stage meta-analysis: HR 0.54, 95% CI 0.35-0.83, P = 0.005; two-stage meta-analysis: HR 0.45, 95% CI 0.22-0.90, P = 0.035, I² = 0%). There were no significant differences for CSS (one-stage meta-analysis: HR 0.53, 95% CI 0.24-1.17, P = 0.116) and OS (one-stage meta-analysis: HR 1.24, 95% CI 0.64-2.42, P = 0.520). Overall risk of bias was moderate across the included studies. CONCLUSIONS: This review observed that m-NMIBC exhibits a poorer response to BCG compared to p-NMIBC, with significantly higher rates of HG-recurrence and disease progression. These observations reflect a potential biological distinction between the 2 entities, and highlight important implications in clinical trial design and risk stratification.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.